|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.300 SEK | -0.76% |
|
-4.13% | +40.69% |
| 22/05 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 15/05 | Sweden's Intervacc Elects New Chair | MT |
Company Valuation: Intervacc AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,669 | 1,313 | 479.4 | 88.61 | 314.9 | 443.1 | - | - |
| Change | - | -50.81% | -63.48% | -81.52% | 255.38% | 40.69% | - | - |
| Enterprise Value (EV) 1 | 2,553 | 1,267 | 391.2 | 54.31 | 154 | 350.1 | 380.1 | 389.1 |
| Change | - | -50.36% | -69.13% | -86.12% | 183.58% | 127.28% | 8.57% | 2.37% |
| P/E | -90.2x | -20.3x | -3.75x | -1.17x | -3.42x | -5.91x | -5.91x | -7.88x |
| PBR | 8.66x | 5.25x | 2.01x | 0.55x | 1x | 2.28x | 2.2x | - |
| PEG | - | -0x | -0.1x | 0x | 0x | 0.3x | - | 0.3x |
| Capitalization / Revenue | 509x | 136x | 59.8x | 7.52x | 15.7x | 25x | 14.7x | 3.66x |
| EV / Revenue | 487x | 131x | 48.8x | 4.61x | 7.67x | 19.8x | 12.6x | 3.22x |
| EV / EBITDA | -110x | -29.1x | -5.67x | -0.92x | -3.27x | -5.52x | -5.76x | -10.7x |
| EV / EBIT | -86.9x | -19.7x | -4.18x | -0.7x | -1.84x | -4.25x | -4.48x | -7.02x |
| EV / FCF | -53.3x | -16.7x | -8.16x | -1.01x | -2.3x | -4.86x | -5.07x | -6.18x |
| FCF Yield | -1.88% | -5.99% | -12.3% | -99.2% | -43.4% | -20.6% | -19.7% | -16.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.59 | -1.28 | -1.69 | -1 | -0.27 | -0.22 | -0.22 | -0.165 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.241 | 9.684 | 8.015 | 11.79 | 20.09 | 17.7 | 30.05 | 121 |
| EBITDA 1 | -23.24 | -43.56 | -68.98 | -58.75 | -47.09 | -63.45 | -65.95 | -36.5 |
| EBIT 1 | -29.39 | -64.41 | -93.58 | -77.28 | -83.5 | -82.35 | -84.85 | -55.4 |
| Net income 1 | -29.38 | -64.16 | -102.9 | -75.52 | -80.82 | -80.8 | -83.65 | -66 |
| Net Debt 1 | -115.5 | -45.52 | -88.2 | -34.3 | -160.9 | -93 | -63 | -54 |
| Reference price 2 | 53.200 | 26.000 | 6.330 | 1.170 | 0.924 | 1.300 | 1.300 | 1.300 |
| Nbr of stocks (in thousands) | 50,160 | 50,491 | 75,736 | 75,736 | 3,40,813 | 3,40,813 | - | - |
| Announcement Date | 18/02/22 | 17/02/23 | 16/02/24 | 13/02/25 | 17/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.95x | 19.97x | -5.57x | - | 4.62Cr | |
| 35.02x | 8.81x | 27.34x | 0.05% | 5.77TCr | |
| 19.79x | 6.09x | 13.27x | 1.53% | 5.27TCr | |
| -42.68x | 14.17x | -41.28x | -.--% | 2.45TCr | |
| -18.74x | 4.62x | -8.07x | -.--% | 2.38TCr | |
| 24.1x | 4.75x | 12.43x | -.--% | 1.93TCr | |
| 24.43x | 4.87x | 15.9x | -.--% | 1.78TCr | |
| 51.77x | 21.11x | 56.65x | 0.05% | 1.73TCr | |
| -536.63x | 36.92x | -4116.16x | -.--% | 1.53TCr | |
| 17.96x | 5.22x | 12.19x | -.--% | 1.43TCr | |
| Average | -43.09x | 12.65x | -403.33x | 0.18% | 2.43TCr | |
| Weighted average by Cap. | -18.86x | 10.17x | -247.84x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IVACC Stock
- Valuation Intervacc AB
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
